William Vickery joins Hybrigenics
pharmafile | December 8, 2010 | Appointment | Research and Development | Hybrigenics, William Vickery, appointment, research and development
Paris-based biopharmaceutical company Hybrigenics has appointed William Vickery to the newly-created position of head of corporate and business development.
He previously worked at ExonHit Therapeutics as senior director of business development. Prior to joining ExonHit Therapeutics in 2006 and since 2003, William served as a business development director of Roche Pharmaceuticals in the US
From 2000 to 2003, he held various positions at Roche Pharmaceuticals headquarters in Switzerland, including business development responsibilities for CNS and metabolic diseases.
Hybrigenics focuses on the research and development of new cancer treatments and has a fully-owned subsidiary specialised in protein interactions services.
Its lead candidate is inecalcitol, a vitamin D analogue for the treatment of hormone-refractory prostate cancer in combination with Sanofi-Aventis’ Taxotere.
“The addition of William Vickery to our management line-up is key to implementing our top priority strategy which is now focused on partnering inecalcitol for further clinical co-development in prostate cancer. His experience and track record both in pharma and biotech organisations will be extremely valuable,” said Remi Delansorne, Hybrigenics’ chief executive.
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






